David F. Stern, PhD
Research & Publications
Biography
News
Locations
Research Summary
The HER-2/Neu/ErbB-2 receptor tyrosine kinase is a major human oncogene and a validated therapeutic target in breast cancer. We are investigating the normal and carcinogenic functions of HER2 and other EGF receptor family kinases to understand how they cause cancers and how they can best be treated. An important practical problem with new, targeted cancer therapies is linking patients to therapies that match the specific alterations in their cancers. We are pursuing high throughput genetic and proteomic approaches to this problem.
Specialized Terms: Cancer Biology; Signal transduction by HER2/ErbB2 and other EGF family receptor tyrosine kinases; EGF family receptors in breast cancer and mammary development; DNA damage checkpoint signaling; Functional and genetic analysis of cancer; Melanoma
Extensive Research Description
1. The receptor tyrosine kinase ErbB2/HER2 drives 25% of breast cancers. This receptor is the target for two drugs in use for breast cancer treatment, Herceptin/Trastuzumab and Tykerb/Lapatinib. In order to understand why this receptor is so important in human cancer, and to improve therapeutic targeting of ErbB2/HER2, we investigate normal and pathological functions of this receptor in mammary tissue. Our work spans from fundamental studies on signal transduction to analysis of ERBB2 in human cancer. ERBB2 works in close partnership with other members of the EGF receptor (ERBB family) of tyrosine kinases, so we also study differential signaling by the three related receptors (EGF receptor [HER]), ERBB3 [HER3], ErbB4[HER4).
2. The growing availability of cancer drugs that target receptors and other signaling proteins has created a need to develop integrated methods for best matching of patients to the appropriate target drugs. We are investigating use of DNA-based and functional approaches for predicting response to targeted therapies, in breast cancer, lung cancer, pancreatic cancer, and melanoma.
Coauthors
Research Interests
Breast Neoplasms; DNA Damage; Melanoma; Neoplasms; Pathology; Signal Transduction
Selected Publications
- Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancerColavito SA, Platt JT, Held MA, Liu Z, Sokup R, Stern DF. Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer Oncotarget 2019, 10: 4822-4839. PMID: 31448050, PMCID: PMC6690678, DOI: 10.18632/oncotarget.27104.
- Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptakeHaskins JW, Zhang S, Means RE, Kelleher JK, Cline GW, Canfrán-Duque A, Suárez Y, Stern DF. Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake Science Signaling 2015, 8: ra111. PMID: 26535009, PMCID: PMC4666504, DOI: 10.1126/scisignal.aac5124.
- Phosphoproteomic Screen Identifies Potential Therapeutic Targets in MelanomaTworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF. Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma Molecular Cancer Research 2011, 9: 801-812. PMID: 21521745, PMCID: PMC3117976, DOI: 10.1158/1541-7786.mcr-10-0512.
- Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug ScreeningHeld MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening Cancer Discovery 2013, 3: 52-67. PMID: 23239741, PMCID: PMC3546137, DOI: 10.1158/2159-8290.cd-12-0408.
- Microcephalin Is a DNA Damage Response Protein Involved in Regulation of CHK1 and BRCA1 * ♦Xu X, Lee J, Stern DF. Microcephalin Is a DNA Damage Response Protein Involved in Regulation of CHK1 and BRCA1 * ♦ Journal Of Biological Chemistry 2004, 279: 34091-34094. PMID: 15220350, DOI: 10.1074/jbc.c400139200.
- ErbB2 is required for ductal morphogenesis of the mammary glandJackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF. ErbB2 is required for ductal morphogenesis of the mammary gland Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 17138-17143. PMID: 15569931, PMCID: PMC535384, DOI: 10.1073/pnas.0407057101.
- Polo-like Kinase 1 and Chk2 Interact and Co-localize to Centrosomes and the Midbody*Tsvetkov L, Xu X, Li J, Stern DF. Polo-like Kinase 1 and Chk2 Interact and Co-localize to Centrosomes and the Midbody* Journal Of Biological Chemistry 2002, 278: 8468-8475. PMID: 12493754, DOI: 10.1074/jbc.m211202200.
- NFBD1/KIAA0170 Is a Chromatin-associated Protein Involved in DNA Damage Signaling Pathways*Xu X, Stern DF. NFBD1/KIAA0170 Is a Chromatin-associated Protein Involved in DNA Damage Signaling Pathways* Journal Of Biological Chemistry 2002, 278: 8795-8803. PMID: 12499369, DOI: 10.1074/jbc.m211392200.
- Rad9 Phosphorylation Sites Couple Rad53 to the Saccharomyces cerevisiae DNA Damage CheckpointSchwartz MF, Duong JK, Sun Z, Morrow JS, Pradhan D, Stern DF. Rad9 Phosphorylation Sites Couple Rad53 to the Saccharomyces cerevisiae DNA Damage Checkpoint Molecular Cell 2002, 9: 1055-1065. PMID: 12049741, DOI: 10.1016/s1097-2765(02)00532-4.
- Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer InterfaceBurke C, Stern D. Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer Interface Molecular And Cellular Biology 1998, 18: 5371-5379. PMID: 9710621, PMCID: PMC109122, DOI: 10.1128/mcb.18.9.5371.
- Specificity within the EGF family/ErbB receptor family signaling networkRiese D, Stern D. Specificity within the EGF family/ErbB receptor family signaling network BioEssays 1998, 20: 41-48. PMID: 9504046, DOI: 10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v.
- Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.DiGiovanna MP, Stern DF. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Research 1995, 55: 1946-55. PMID: 7728765.
- The Cellular Response to Neuregulins Is Governed by Complex Interactions of the erbB Receptor FamilyRiese D, van Raaij T, Plowman G, Andrews G, Stern D. The Cellular Response to Neuregulins Is Governed by Complex Interactions of the erbB Receptor Family Molecular And Cellular Biology 1995, 15: 5770-5776. PMID: 7565730, PMCID: PMC230829, DOI: 10.1128/mcb.15.10.5770.
- Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.Bangalore L, Tanner AJ, Laudano AP, Stern DF. Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor. Proceedings Of The National Academy Of Sciences Of The United States Of America 1992, 89: 11637-11641. PMID: 1280833, PMCID: PMC50608, DOI: 10.1073/pnas.89.23.11637.
- EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.Stern DF, Kamps MP. EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. The EMBO Journal 1988, 7: 995-1001. PMID: 3261240, PMCID: PMC454426, DOI: 10.1002/j.1460-2075.1988.tb02906.x.
- p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Molecular And Cellular Biology 1986, 6: 1729-1740. PMID: 2878363, PMCID: PMC367701, DOI: 10.1128/mcb.6.5.1729.
- Coronavirus multiplication strategy. I. Identification and characterization of virus-specified RNA.Stern DF, Kennedy SI. Coronavirus multiplication strategy. I. Identification and characterization of virus-specified RNA. Journal Of Virology 1980, 34: 665-74. PMID: 6247505, PMCID: PMC288755.
- Coronavirus multiplication: locations of genes for virion proteins on the avian infectious bronchitis virus genome.Stern DF, Sefton BM. Coronavirus multiplication: locations of genes for virion proteins on the avian infectious bronchitis virus genome. Journal Of Virology 1984, 50: 22-9. PMID: 6321790, PMCID: PMC255576, DOI: 10.1128/jvi.50.1.22-29.1984.
- Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populationsPatwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L, Hatzis C. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations Npj Breast Cancer 2021, 7: 60. PMID: 34040000, PMCID: PMC8154902, DOI: 10.1038/s41523-021-00270-4.
- Identifying modules of cooperating cancer driversKlein MI, Cannataro VL, Townsend JP, Newman S, Stern DF, Zhao H. Identifying modules of cooperating cancer drivers Molecular Systems Biology 2021, 17: e9810. PMID: 33769711, PMCID: PMC7995435, DOI: 10.15252/msb.20209810.
- Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase InhibitionGale M, Li Y, Cao J, Liu ZZ, Holmbeck MA, Zhang M, Lang SM, Wu L, Do Carmo M, Gupta S, Aoshima K, DiGiovanna MP, Stern DF, Rimm DL, Shadel GS, Chen X, Yan Q. Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition Cancer Research 2020, 80: 524-535. PMID: 31690671, PMCID: PMC7002225, DOI: 10.1158/0008-5472.can-18-3985.
- Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancerTheodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer Pigment Cell & Melanoma Research 2018, 32: 292-302. PMID: 30281931, PMCID: PMC6590911, DOI: 10.1111/pcmr.12742.
- Keeping Tumors Out of the MAPK Fitness ZoneStern DF. Keeping Tumors Out of the MAPK Fitness Zone Cancer Discovery 2018, 8: 20-23. PMID: 29311225, DOI: 10.1158/2159-8290.cd-17-1243.
- GRAPE: a pathway template method to characterize tissue-specific functionality from gene expression profilesKlein MI, Stern DF, Zhao H. GRAPE: a pathway template method to characterize tissue-specific functionality from gene expression profiles BMC Bioinformatics 2017, 18: 317. PMID: 28651562, PMCID: PMC5485588, DOI: 10.1186/s12859-017-1711-z.
- p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein SynthesisTheodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis Journal Of Investigative Dermatology 2017, 137: 2187-2196. PMID: 28599981, PMCID: PMC6342201, DOI: 10.1016/j.jid.2016.12.033.
- Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation InhibitorLangdon CG, Platt JT, Means RE, Iyidogan P, Mamillapalli R, Klein M, Held MA, Lee JW, Koo JS, Hatzis C, Hochster HS, Stern DF. Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor Molecular Cancer Therapeutics 2017, 16: 1041-1053. PMID: 28292938, PMCID: PMC5457712, DOI: 10.1158/1535-7163.mct-16-0794.
- 789 Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanomaTheodosakis N, Langdon C, Micevic G, Stern D, Bosenberg M. 789 Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma Journal Of Investigative Dermatology 2017, 137: s136. DOI: 10.1016/j.jid.2017.02.814.
- Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast CancerWali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer Cancer Research 2017, 77: 566-578. PMID: 27872098, PMCID: PMC5582957, DOI: 10.1158/0008-5472.can-16-1901.
- A Computational Approach for Identifying Synergistic Drug CombinationsGayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O. A Computational Approach for Identifying Synergistic Drug Combinations PLOS Computational Biology 2017, 13: e1005308. PMID: 28085880, PMCID: PMC5234777, DOI: 10.1371/journal.pcbi.1005308.
- Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screeningWali V, Langdon C, Held M, Platt J, Safonov A, Aktas B, Stern D, Pusztai L, Hatzis C. Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screening Cancer Research 2016, 76: p6-13-06-p6-13-06. DOI: 10.1158/1538-7445.sabcs15-p6-13-06.
- Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival – Evidence from TCGA Pan-Cancer DataHuang X, Stern DF, Zhao H. Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival – Evidence from TCGA Pan-Cancer Data Scientific Reports 2016, 6: 20567. PMID: 26837275, PMCID: PMC4738355, DOI: 10.1038/srep20567.
- PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancerJeong J, VanHouten JN, Dann P, Kim W, Sullivan C, Yu H, Liotta L, Espina V, Stern DF, Friedman PA, Wysolmerski JJ. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: e282-e290. PMID: 26729871, PMCID: PMC4725473, DOI: 10.1073/pnas.1516138113.
- SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cellsLangdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells Oncotarget 2015, 6: 37410-37425. PMID: 26485762, PMCID: PMC4741938, DOI: 10.18632/oncotarget.6138.
- Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinomaLangdon C, Wiedemann N, Held M, Platt J, Mamillapalli R, Iyidogan P, Theodosakis N, Levy F, Robichon D, Zanna C, Vuagniaux G, Sorensen M, Wang S, Bosenberg M, Stern D. Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma 2015, 2529-2529. DOI: 10.1158/1538-7445.am2015-2529.
- BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell VolumeTheodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume Molecular Cancer Therapeutics 2015, 14: 1680-1692. PMID: 25948295, PMCID: PMC4497841, DOI: 10.1158/1535-7163.mct-15-0080.
- The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitorsLangdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z, Bosenberg MW, Stern DF. The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitors Pigment Cell & Melanoma Research 2015, 28: 417-430. PMID: 25854919, PMCID: PMC5215495, DOI: 10.1111/pcmr.12376.
- PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic TargetsScortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets Cancer Research 2015, 75: 1399-1412. PMID: 25712345, PMCID: PMC4383687, DOI: 10.1158/0008-5472.can-14-2785.
- Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesisWali VB, Gilmore-Hebert M, Mamillapalli R, Haskins JW, Kurppa KJ, Elenius K, Booth CJ, Stern DF. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis Breast Cancer Research 2014, 16: 501. PMID: 25516216, PMCID: PMC4303208, DOI: 10.1186/s13058-014-0501-z.
- Neuregulin 1–activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migrationHaskins JW, Nguyen DX, Stern DF. Neuregulin 1–activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration Science Signaling 2014, 7: ra116. PMID: 25492965, PMCID: PMC4648367, DOI: 10.1126/scisignal.2005770.
- Abstract 1792: Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancerLangdon C, Wiedemann N, Hajjami H, Held M, Platt J, Vuagniaux G, Bosenberg M, Stern D, Lévy F. Abstract 1792: Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer 2014, 1792-1792. DOI: 10.1158/1538-7445.am2014-1792.
- Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer modelsLangdon C, Wiedemann N, Held M, Platt J, Lévy F, Robichon D, Zanna C, Vuagniaux G, Sorensen M, Wang S, Bosenberg M, Stern D. Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models 2014, 5441-5441. DOI: 10.1158/1538-7445.am2014-5441.
- Significance of glioma-associated oncogene homolog 1 (GLI1)expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathwayColavito SA, Zou MR, Yan Q, Nguyen DX, Stern DF. Significance of glioma-associated oncogene homolog 1 (GLI1)expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway Breast Cancer Research 2014, 16: 444. PMID: 25252859, PMCID: PMC4303124, DOI: 10.1186/s13058-014-0444-4.
- Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial CellsWali VB, Haskins JW, Gilmore-Hebert M, Platt JT, Liu Z, Stern DF. Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells Molecular Cancer Research 2014, 12: 1140-1155. PMID: 24829397, PMCID: PMC4728083, DOI: 10.1158/1541-7786.mcr-13-0637.
- Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment MethodBai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF. Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method PLOS ONE 2013, 8: e79901. PMID: 24278211, PMCID: PMC3836903, DOI: 10.1371/journal.pone.0079901.
- Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells.Langdon C, Wiedemann N, Held M, Platt J, Lévy F, Zanna C, Vuagniaux G, Sorensen M, Wang S, Bosenberg M, Stern D. Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells. Molecular Cancer Therapeutics 2013, 12: a16-a16. DOI: 10.1158/1535-7163.targ-13-a16.
- Abstract B275: Dovitinib as a single-agent or in combination with other small molecule inhibitors for mutant BRAF melanomas.Langdon C, Held M, Koo A, Klein M, Liu Z, Platt J, Stern D. Abstract B275: Dovitinib as a single-agent or in combination with other small molecule inhibitors for mutant BRAF melanomas. Molecular Cancer Therapeutics 2013, 12: b275-b275. DOI: 10.1158/1535-7163.targ-13-b275.
- EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain MetastasisBreindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis Cancer Research 2013, 73: 5053-5065. PMID: 23794705, PMCID: PMC3745527, DOI: 10.1158/0008-5472.can-12-3775.
- MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXLTworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL Pigment Cell & Melanoma Research 2013, 26: 527-541. PMID: 23617806, PMCID: PMC3918898, DOI: 10.1111/pcmr.12110.
- Abstract 1401: Overexpression of HER4 isoforms in transgenic mice reveal isoform-specific role in mammary gland development and carcinogenesis.Wali V, Gilmore-Hebert M, Elenius K, Stern D. Abstract 1401: Overexpression of HER4 isoforms in transgenic mice reveal isoform-specific role in mammary gland development and carcinogenesis. Cancer Research 2013, 73: 1401-1401. DOI: 10.1158/1538-7445.am2013-1401.
- Abstract P3-14-01: Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).Colavito S, Stepansky A, Madan A, Harris L, Hicks J, Bossuyt V, Rimm D, Lannin D, Stern D. Abstract P3-14-01: Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). Cancer Research 2012, 72: p3-14-01-p3-14-01. DOI: 10.1158/0008-5472.sabcs12-p3-14-01.
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaKrauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker J, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma Nature Genetics 2012, 44: 1006-1014. PMID: 22842228, PMCID: PMC3432702, DOI: 10.1038/ng.2359.
- NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53Wilson KA, Colavito SA, Schulz V, Wakefield PH, Sessa W, Tuck D, Stern DF. NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53 Molecular Cancer Research 2011, 9: 766-781. PMID: 21551225, PMCID: PMC3901581, DOI: 10.1158/1541-7786.mcr-10-0317.
- Abstract LB-194: Phosphorylation-dependent dimerization of forkhead-associated domain regulates MDC1 function in response to DNA damageLiu J, Luo S, Stern D, Ye K, Xu X. Abstract LB-194: Phosphorylation-dependent dimerization of forkhead-associated domain regulates MDC1 function in response to DNA damage Cancer Research 2011, 71: lb-194-lb-194. DOI: 10.1158/1538-7445.am2011-lb-194.
- Interactions of ErbB4 and Kap1 Connect the Growth Factor and DNA Damage Response PathwaysGilmore-Hebert M, Ramabhadran R, Stern DF. Interactions of ErbB4 and Kap1 Connect the Growth Factor and DNA Damage Response Pathways Molecular Cancer Research 2010, 8: 1388-1398. PMID: 20858735, PMCID: PMC3901583, DOI: 10.1158/1541-7786.mcr-10-0042.
- Centrosomal Chk2 in DNA damage responses and cell cycle progessionGolan A, Pick E, Tsvetkov L, Nadler Y, Kluger H, Stern DF. Centrosomal Chk2 in DNA damage responses and cell cycle progession Cell Cycle 2010, 9: 2647-2656. PMID: 20581449, PMCID: PMC3233491, DOI: 10.4161/cc.9.13.12121.
- Deciphering Protein Kinase Specificity Through Large-Scale Analysis of Yeast Phosphorylation Site MotifsMok J, Kim PM, Lam HY, Piccirillo S, Zhou X, Jeschke GR, Sheridan DL, Parker SA, Desai V, Jwa M, Cameroni E, Niu H, Good M, Remenyi A, Nianhan J, Sheu YJ, Sassi HE, Sopko R, Chan CS, De Virgilio C, Hollingsworth NM, Lim WA, Stern DF, Stillman B, Andrews BJ, Gerstein MB, Snyder M, Turk BE. Deciphering Protein Kinase Specificity Through Large-Scale Analysis of Yeast Phosphorylation Site Motifs Science Signaling 2010, 3: ra12. PMID: 20159853, PMCID: PMC2846625, DOI: 10.1126/scisignal.2000482.
- Molecular Classification of Normal and Cancer Mammospheres.Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.
- Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cellsAgarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, DiGiovanna MP, Stern DF. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells British Journal Of Cancer 2009, 100: 941-949. PMID: 19240716, PMCID: PMC2661782, DOI: 10.1038/sj.bjc.6604937.
- BRCTing Up Is Hard to DoStern DF. BRCTing Up Is Hard to Do Molecular Cell 2009, 33: 137-138. PMID: 19187753, DOI: 10.1016/j.molcel.2009.01.005.
- ErbB3 is required for ductal morphogenesis in the mouse mammary glandJackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, Stern DF. ErbB3 is required for ductal morphogenesis in the mouse mammary gland Breast Cancer Research 2008, 10: r96. PMID: 19019207, PMCID: PMC2656891, DOI: 10.1186/bcr2198.
- NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathwayWilson KA, Stern DF. NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway Cell Cycle 2008, 7: 3584-3594. PMID: 19001859, PMCID: PMC2763172, DOI: 10.4161/cc.7.22.7102.
- ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast CancerStern DF. ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer Journal Of Mammary Gland Biology And Neoplasia 2008, 13: 215. PMID: 18454306, PMCID: PMC6590701, DOI: 10.1007/s10911-008-9083-7.
- Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancerZito CI, Riches D, Kolmakova J, Simons J, Egholm M, Stern DF. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer Genes Chromosomes And Cancer 2008, 47: 633-638. PMID: 18418848, PMCID: PMC6668724, DOI: 10.1002/gcc.20566.
- Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group BDiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B Journal Of Clinical Oncology 2008, 26: 2364-2372. PMID: 18390970, PMCID: PMC6589994, DOI: 10.1200/jco.2007.13.6580.
- Regulation of the Rad53 protein kinase in signal amplification by oligomer assembly and disassemblyJia-Lin Ma N, Stern DF. Regulation of the Rad53 protein kinase in signal amplification by oligomer assembly and disassembly Cell Cycle 2008, 7: 808-817. PMID: 18239457, DOI: 10.4161/cc.7.6.5595.
- Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, Gassmann M, Muller W, Kent Lloyd KC, Stern DF. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4 Oncogene 2006, 25: 5664-5672. PMID: 16652155, DOI: 10.1038/sj.onc.1209574.
- Global Analysis of Protein Phosphorylation in YeastPtacek J, Devgan G, Michaud G, Zhu H, Zhu X, Fasolo J, Guo H, Jona G, Breitkreutz A, Sopko R, McCartney R, Schmidt M, Rachidi N, Lee S, Mah A, Meng L, Stark M, Stern D, De Virgilio C, Tyers M, Andrews B, Gerstein M, Schweitzer B, Predki P, Snyder M. Global Analysis of Protein Phosphorylation in Yeast The FASEB Journal 2006, 20: a1308-a1308. DOI: 10.1096/fasebj.20.5.a1308.
- Activation of the Checkpoint Kinase Rad53 by the Phosphatidyl Inositol Kinase-like Kinase Mec1*Ma JL, Lee SJ, Duong JK, Stern DF. Activation of the Checkpoint Kinase Rad53 by the Phosphatidyl Inositol Kinase-like Kinase Mec1* Journal Of Biological Chemistry 2005, 281: 3954-3963. PMID: 16365046, DOI: 10.1074/jbc.m507508200.
- Global analysis of protein phosphorylation in yeastPtacek J, Devgan G, Michaud G, Zhu H, Zhu X, Fasolo J, Guo H, Jona G, Breitkreutz A, Sopko R, McCartney RR, Schmidt MC, Rachidi N, Lee SJ, Mah AS, Meng L, Stark MJ, Stern DF, De Virgilio C, Tyers M, Andrews B, Gerstein M, Schweitzer B, Predki PF, Snyder M. Global analysis of protein phosphorylation in yeast Nature 2005, 438: 679-684. PMID: 16319894, DOI: 10.1038/nature04187.
- In situ Detection of Specific DNA Double Strand Breaks using Rolling Circle AmplificationLi J, Young CS, Lizardi PM, Stern DF. In situ Detection of Specific DNA Double Strand Breaks using Rolling Circle Amplification Cell Cycle 2005, 4: 1767-1773. PMID: 16294038, DOI: 10.4161/cc.4.12.2211.
- Neuregulin-regulated gene expression in mammary carcinoma cellsAmin DN, Tuck D, Stern DF. Neuregulin-regulated gene expression in mammary carcinoma cells Experimental Cell Research 2005, 309: 12-23. PMID: 15963498, DOI: 10.1016/j.yexcr.2005.04.034.
- DNA Damage Regulates Chk2 Association with Chromatin*Li J, Stern DF. DNA Damage Regulates Chk2 Association with Chromatin* Journal Of Biological Chemistry 2005, 280: 37948-37956. PMID: 16150728, DOI: 10.1074/jbc.m509299200.
- Phosphoproteomics for oncology discovery and treatmentStern DF. Phosphoproteomics for oncology discovery and treatment Expert Opinion On Therapeutic Targets 2005, 9: 851-860. PMID: 16083347, DOI: 10.1517/14728222.9.4.851.
- Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer PatientsDiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor AD. Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients Journal Of Clinical Oncology 2005, 23: 1152-1160. PMID: 15718311, DOI: 10.1200/jco.2005.09.055.
- The Plk1 Polo Box Domain Mediates a Cell Cycle and DNA Damage Regulated Interaction with Chk2Tsvetkov LM, Tsekova RT, Xu X, Stern DF. The Plk1 Polo Box Domain Mediates a Cell Cycle and DNA Damage Regulated Interaction with Chk2 Cell Cycle 2005, 4: 602-610. PMID: 15876876, DOI: 10.4161/cc.4.4.1599.
- Regulation of CHK2 by DNA-dependent Protein Kinase*Li J, Stern DF. Regulation of CHK2 by DNA-dependent Protein Kinase* Journal Of Biological Chemistry 2005, 280: 12041-12050. PMID: 15668230, DOI: 10.1074/jbc.m412445200.
- Interaction of Chromatin-associated Plk1 and Mcm7*Tsvetkov L, Stern DF. Interaction of Chromatin-associated Plk1 and Mcm7* Journal Of Biological Chemistry 2005, 280: 11943-11947. PMID: 15654075, DOI: 10.1074/jbc.m413514200.
- Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast CancerModi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer Cancer Investigation 2005, 23: 483-487. PMID: 16203655, DOI: 10.1080/07357900500201301.
- Phosphorylation of Plk1 at S137 and T210 is Inhibited in Response to DNA DamageTsvetkov L, Stern DF. Phosphorylation of Plk1 at S137 and T210 is Inhibited in Response to DNA Damage Cell Cycle 2004, 4: 166-171. PMID: 15611664, DOI: 10.4161/cc.4.1.1348.
- More than a Marker… Phosphorylated Akt in Prostate CarcinomaStern DF. More than a Marker… Phosphorylated Akt in Prostate Carcinoma Clinical Cancer Research 2004, 10: 6407-6410. PMID: 15475426, DOI: 10.1158/1078-0432.ccr-04-1783.
- A Ddc2-Rad53 Fusion Protein Can Bypass the Requirements for RAD9 and MRC1 in Rad53 ActivationLee SJ, Duong JK, Stern DF. A Ddc2-Rad53 Fusion Protein Can Bypass the Requirements for RAD9 and MRC1 in Rad53 Activation Molecular Biology Of The Cell 2004, 15: 5443-5455. PMID: 15456903, PMCID: PMC532024, DOI: 10.1091/mbc.e04-07-0608.
- Establishment of a Cell-Free System to Study the Activation of Chk2Xu X, Stern DF. Establishment of a Cell-Free System to Study the Activation of Chk2 2004, 280: 165-174. PMID: 15187252, DOI: 10.1385/1-59259-788-2:165.
- Gene expression profiling of ErbB receptor and ligand-dependent transcriptionAmin DN, Perkins AS, Stern DF. Gene expression profiling of ErbB receptor and ligand-dependent transcription Oncogene 2003, 23: 1428-1438. PMID: 14973552, DOI: 10.1038/sj.onc.1207257.
- NFBD1/MDC1 regulates ionizing radiation‐induced focus formation by DNA checkpoint signaling and repair factorsXu X, Stern DF. NFBD1/MDC1 regulates ionizing radiation‐induced focus formation by DNA checkpoint signaling and repair factors The FASEB Journal 2003, 17: 1842-1848. PMID: 14519663, DOI: 10.1096/fj.03-0310com.
- Rad53 Phosphorylation Site Clusters Are Important for Rad53 Regulation and SignalingLee SJ, Schwartz MF, Duong JK, Stern DF. Rad53 Phosphorylation Site Clusters Are Important for Rad53 Regulation and Signaling Molecular And Cellular Biology 2003, 23: 6300-6314. PMID: 12917350, PMCID: PMC180918, DOI: 10.1128/mcb.23.17.6300-6314.2003.
- FHA Domain-Mediated DNA Checkpoint Regulation of Rad53Schwartz MF, Lee SJ, Duong JK, Eminaga S, Stern DF. FHA Domain-Mediated DNA Checkpoint Regulation of Rad53 Cell Cycle 2003, 2: 381-394. PMID: 12851493, DOI: 10.4161/cc.2.4.457.
- Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethalityTidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 8281-8286. PMID: 12824469, PMCID: PMC166220, DOI: 10.1073/pnas.1436402100.
- ErbBs in mammary developmentStern DF. ErbBs in mammary development Experimental Cell Research 2003, 284: 89-98. PMID: 12648468, DOI: 10.1016/s0014-4827(02)00103-9.
- Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Research 2002, 62: 6667-73. PMID: 12438265.
- Production of Antibodies that Recognize Specific Tyrosine‐Phosphorylated PeptidesDiGiovanna MP, Stern DF, Roussel RR. Production of Antibodies that Recognize Specific Tyrosine‐Phosphorylated Peptides Current Protocols In Immunology 2002, 50: 11.6.1-11.6.19. PMID: 18432869, DOI: 10.1002/0471142735.im0101s50.
- Chk2 Activation and Phosphorylation-Dependent OligomerizationXu X, Tsvetkov LM, Stern DF. Chk2 Activation and Phosphorylation-Dependent Oligomerization Molecular And Cellular Biology 2002, 22: 4419-4432. PMID: 12024051, PMCID: PMC133858, DOI: 10.1128/mcb.22.12.4419-4432.2002.
- Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated PeptidesDiGiovanna MP, Roussel RR, Stern DF. Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated Peptides Current Protocols In Cell Biology 2002, 13: 16.6.1-16.6.18. PMID: 18228399, DOI: 10.1002/0471143030.cb1606s13.
- HER-2 testing in prostate carcinoma.Stern DF. HER-2 testing in prostate carcinoma. Cancer Journal (Sudbury, Mass.) 2001, 7: 372-4. PMID: 11693894.
- PhosphoproteomicsStern D. Phosphoproteomics Experimental And Molecular Pathology 2001, 70: 327-331. PMID: 11418011, DOI: 10.1006/exmp.2001.2370.
- Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone ReceptorsClaus E, Chu P, Howe C, Davison T, Stern D, Carter D, DiGiovanna M. Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors Experimental And Molecular Pathology 2001, 70: 303-316. PMID: 11418009, DOI: 10.1006/exmp.2001.2366.
- Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.Thor AD, Liu S, Edgerton S, Moore D, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. Journal Of Clinical Oncology 2000, 18: 3230-9. PMID: 10986055, DOI: 10.1200/jco.2000.18.18.3230.
- Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinasesStern D. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases Breast Cancer Research 2000, 2: 176. PMID: 11250707, PMCID: PMC138772, DOI: 10.1186/bcr51.
- Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated PeptidesDiGiovanna M, Roussel R, Stern D. Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated Peptides Current Protocols In Molecular Biology 2000, 50: 18.6.1-18.6.19. PMID: 18265171, DOI: 10.1002/0471142727.mb1806s50.
- Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesisRussell K, Stern D, Polverini P, Bender J. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis American Journal Of Physiology 1999, 277: h2205-h2211. PMID: 10600838, DOI: 10.1152/ajpheart.1999.277.6.h2205.
- Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during LactationJones F, Welte T, Fu X, Stern D. Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation Journal Of Cell Biology 1999, 147: 77-88. PMID: 10508857, PMCID: PMC2164978, DOI: 10.1083/jcb.147.1.77.
- Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactationJones F, Stern D. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation Oncogene 1999, 18: 3481-3490. PMID: 10376526, DOI: 10.1038/sj.onc.1202698.
- Active signaling by Neu in transgenic miceDiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF. Active signaling by Neu in transgenic mice Oncogene 1998, 17: 1877-1884. PMID: 9778054, DOI: 10.1038/sj.onc.1202091.
- Rad53 FHA Domain Associated with Phosphorylated Rad9 in the DNA Damage CheckpointSun Z, Hsiao J, Fay D, Stern D. Rad53 FHA Domain Associated with Phosphorylated Rad9 in the DNA Damage Checkpoint Science 1998, 281: 272-274. PMID: 9657725, DOI: 10.1126/science.281.5374.272.
- Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2*Riese D, Komurasaki T, Plowman G, Stern D. Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2* Journal Of Biological Chemistry 1998, 273: 11288-11294. PMID: 9556621, DOI: 10.1074/jbc.273.18.11288.
- Ligands for ErbB-family receptors encoded by a neuregulin-like geneChang H, Riese II D, Gilbert W, Stern D, McMahan UJ. Ligands for ErbB-family receptors encoded by a neuregulin-like gene Nature 1997, 387: 509-512. PMID: 9168114, DOI: 10.1038/387509a0.
- Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformationBurke C, Lemmon M, Coren B, Engelman D, Stern D. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation Oncogene 1997, 14: 687-696. PMID: 9038376, DOI: 10.1038/sj.onc.1200873.
- Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells*Kannan S, De Santis M, Lohmeyer M, David J, Smith G, Hynes N, Seno M, Brandt R, Bianco C, Persico G, Kenney N, Normanno N, Martinez-Lacaci I, Ciardiello F, Stern D, Gullick W, Salomon D. Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells* Journal Of Biological Chemistry 1997, 272: 3330-3335. PMID: 9013573, DOI: 10.1074/jbc.272.6.3330.
- Mutations in SPK1/RAD53 that specifically abolish checkpoint but not growth-related functionsFay DS, Sun Z, Stern D. Mutations in SPK1/RAD53 that specifically abolish checkpoint but not growth-related functions Current Genetics 1997, 31: 97-105. PMID: 9021124, DOI: 10.1007/s002940050181.
- A role for DNA primase in coupling DNA replication to DNA damage responseMarini F, Pellicioli A, Paciotti V, Lucchini G, Plevani P, Stern D, Foiani M. A role for DNA primase in coupling DNA replication to DNA damage response The EMBO Journal 1997, 16: 639-650. PMID: 9034345, PMCID: PMC1169666, DOI: 10.1093/emboj/16.3.639.
- Endothelial Nitric Oxide Synthase Is Regulated by Tyrosine Phosphorylation and Interacts with Caveolin-1*García-Cardeña G, Fan R, Stern D, Liu J, Sessa W. Endothelial Nitric Oxide Synthase Is Regulated by Tyrosine Phosphorylation and Interacts with Caveolin-1* Journal Of Biological Chemistry 1996, 271: 27237-27240. PMID: 8910295, DOI: 10.1074/jbc.271.44.27237.
- Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumoursDiGiovanna M, Carter D, Flynn S, Stern D. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours British Journal Of Cancer 1996, 74: 802-806. PMID: 8795585, PMCID: PMC2074709, DOI: 10.1038/bjc.1996.439.
- Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli.Jones FE, Jerry DJ, Guarino BC, Andrews GC, Stern DF. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Molecular Cancer Research 1996, 7: 1031-8. PMID: 8853899.
- The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4*Riese D, Kim E, Elenius K, Buckley S, Klagsbrun M, Plowman G, Stern D. The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4* Journal Of Biological Chemistry 1996, 271: 20047-20052. PMID: 8702723, DOI: 10.1074/jbc.271.33.20047.
- Heregulin-Induced Growth Factor Receptor Signaling and Breast Carcinogenesis.Riese D, Stern D. Heregulin-Induced Growth Factor Receptor Signaling and Breast Carcinogenesis. 1996 DOI: 10.21236/ada315700.
- Spk1/Rad53 is regulated by Mec1-dependent protein phosphorylation in DNA replication and damage checkpoint pathways.Sun Z, Fay DS, Marini F, Foiani M, Stern DF. Spk1/Rad53 is regulated by Mec1-dependent protein phosphorylation in DNA replication and damage checkpoint pathways. Genes & Development 1996, 10: 395-406. PMID: 8600024, DOI: 10.1101/gad.10.4.395.
- Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. American Journal Of Pathology 1996, 148: 549-58. PMID: 8579117, PMCID: PMC1861670.
- Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.Riese DJ, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, Stern DF. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 1996, 12: 345-53. PMID: 8570211.
- ScSpk1 Spk1 (S. cerevisiae)Zheng P, Fay D, Stern D. ScSpk1 Spk1 (S. cerevisiae) 1995, 126-127. DOI: 10.1016/b978-012324719-3/50028-5.
- The biology of erbB-2/nue/HER-2 and its role in cancerHynes N, Stern D. The biology of erbB-2/nue/HER-2 and its role in cancer Biochimica Et Biophysica Acta 1994, 1198: 165-184. PMID: 7819273, DOI: 10.1016/0304-419x(94)90012-4.
- SPK1 is an essential S-phase-specific gene of Saccharomyces cerevisiae that encodes a nuclear serine/threonine/tyrosine kinase.Zheng P, Fay DS, Burton J, Xiao H, Pinkham JL, Stern DF. SPK1 is an essential S-phase-specific gene of Saccharomyces cerevisiae that encodes a nuclear serine/threonine/tyrosine kinase. Molecular And Cellular Biology 1993, 13: 5829-5842. PMID: 8355715, PMCID: PMC360328, DOI: 10.1128/mcb.13.9.5829.
- An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu.Cao H, Bangalore L, Dompé C, Bormann BJ, Stern DF. An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu. Journal Of Biological Chemistry 1992, 267: 20489-20492. PMID: 1356980, DOI: 10.1016/s0021-9258(19)88728-8.
- A subdomain in the transmembrane domain is necessary for p185neu* activation.Cao H, Bangalore L, Bormann BJ, Stern DF. A subdomain in the transmembrane domain is necessary for p185neu* activation. The EMBO Journal 1992, 11: 923-32. PMID: 1347745, PMCID: PMC556533, DOI: 10.1002/j.1460-2075.1992.tb05131.x.
- Membrane-anchored forms of EGF stimulate focus formation and intercellular communication.Dobashi Y, Stern DF. Membrane-anchored forms of EGF stimulate focus formation and intercellular communication. Oncogene 1991, 6: 1151-9. PMID: 1861865.
- TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.Cao H, Decker S, Stern DF. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. Oncogene 1991, 6: 705-11. PMID: 1675782.
- Spk1, a new kinase from Saccharomyces cerevisiae, phosphorylates proteins on serine, threonine, and tyrosine.Stern DF, Zheng P, Beidler DR, Zerillo C. Spk1, a new kinase from Saccharomyces cerevisiae, phosphorylates proteins on serine, threonine, and tyrosine. Molecular And Cellular Biology 1991, 11: 987-1001. PMID: 1899289, PMCID: PMC359764, DOI: 10.1128/mcb.11.2.987.
- Antiphosphotyrosine antibodies in oncogene and receptor research.Stern DF. Antiphosphotyrosine antibodies in oncogene and receptor research. Methods In Enzymology 1991, 198: 494-501. PMID: 1713286.
- Construction and expression of transforming gene resulting from fusion of basic fibroblast growth factor gene with signal peptide sequenceRogelj S, Stern D, Klagsbrun M. Construction and expression of transforming gene resulting from fusion of basic fibroblast growth factor gene with signal peptide sequence 1991, 198: 117-124. PMID: 1906971, DOI: 10.1016/0076-6879(91)98013-v.
- The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.Connelly PA, Stern DF. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Proceedings Of The National Academy Of Sciences Of The United States Of America 1990, 87: 6054-6057. PMID: 1974718, PMCID: PMC54470, DOI: 10.1073/pnas.87.16.6054.
- Tyrosine phosphorylation is an early and specific event involved in primary keratinocyte differentiation.Filvaroff E, Stern DF, Dotto GP. Tyrosine phosphorylation is an early and specific event involved in primary keratinocyte differentiation. Molecular And Cellular Biology 1990, 10: 1164-1173. PMID: 1689456, PMCID: PMC360987, DOI: 10.1128/mcb.10.3.1164.
- The Ick tyrosine protein kinase interacts with the cytoplasmic tail of the CD4 glycoprotein through its unique amino-terminal domainShaw A, Amrein K, Hammond C, Stern D, Sefton B, Rose J. The Ick tyrosine protein kinase interacts with the cytoplasmic tail of the CD4 glycoprotein through its unique amino-terminal domain Cell 1989, 59: 627-636. PMID: 2582490, DOI: 10.1016/0092-8674(89)90008-1.
- Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.Stern DF, Kamps MP, Cao H. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Molecular And Cellular Biology 1988, 8: 3969-3973. PMID: 2464744, PMCID: PMC365461, DOI: 10.1128/mcb.8.9.3969.
- Construction of a Novel Oncogene Based on Synthetic Sequences Encoding Epidermal Growth FactorStern DF, Hare DL, Cecchini MA, Weinberg RA. Construction of a Novel Oncogene Based on Synthetic Sequences Encoding Epidermal Growth Factor Science 1987, 235: 321-324. PMID: 3492043, DOI: 10.1126/science.3492043.
- p185, a Product of the neu Proto-Oncogene, Is a Receptorlike Protein Associated with Tyrosine Kinase ActivityStern D, Heffernan P, Weinberg R. p185, a Product of the neu Proto-Oncogene, Is a Receptorlike Protein Associated with Tyrosine Kinase Activity Molecular And Cellular Biology 1986, 6: 1729-1740. DOI: 10.1128/mcb.6.5.1729-1740.1986.
- p185, a Product of the neu Proto-Oncogene, Is a Receptorlike Protein Associated with Tyrosine Kinase ActivityStern D, Heffernan P, Weinberg R. p185, a Product of the neu Proto-Oncogene, Is a Receptorlike Protein Associated with Tyrosine Kinase Activity Molecular And Cellular Biology 1986, 6: 1729-1740. DOI: 10.1128/mcb.6.5.1729-1740.1986.
- Differential responsiveness of myc- and ras-transfected cells to growth factors: selective stimulation of myc-transfected cells by epidermal growth factor.Stern DF, Roberts AB, Roche NS, Sporn MB, Weinberg RA. Differential responsiveness of myc- and ras-transfected cells to growth factors: selective stimulation of myc-transfected cells by epidermal growth factor. Molecular And Cellular Biology 1986, 6: 870-877. PMID: 3022135, PMCID: PMC367587, DOI: 10.1128/mcb.6.3.870.
- Development of monoclonal antibodies reactive with the product of the neu oncogene.Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Development of monoclonal antibodies reactive with the product of the neu oncogene. Symposium On Fundamental Cancer Research 1986, 38: 277-89. PMID: 3749645.
- Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.Hung MC, Schechter AL, Chevray PY, Stern DF, Weinberg RA. Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. Proceedings Of The National Academy Of Sciences Of The United States Of America 1986, 83: 261-264. PMID: 3001730, PMCID: PMC322837, DOI: 10.1073/pnas.83.2.261.
- Analysis of the neu-Encoded Protein and Its Mechanism of Oncogenic ActivationBargmann C, Stern D, Drebin J, Schechter A, Weinberg R. Analysis of the neu-Encoded Protein and Its Mechanism of Oncogenic Activation 1986, 63-68. DOI: 10.1007/978-3-642-71686-7_7.
- Oncogenes in neural tumorsBreakefield X, Stern D. Oncogenes in neural tumors Trends In Neurosciences 1986, 9: 150-155. DOI: 10.1016/0166-2236(86)90051-2.
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesDrebin J, Link V, Stern D, Weinberg R, Greene M. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies Cell 1985, 41: 695-706. PMID: 2860972, DOI: 10.1016/s0092-8674(85)80050-7.
- Type beta transforming growth factor: a bifunctional regulator of cellular growth.Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proceedings Of The National Academy Of Sciences Of The United States Of America 1985, 82: 119-123. PMID: 3871521, PMCID: PMC396983, DOI: 10.1073/pnas.82.1.119.
- Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogeneDrebin J, Stern D, Link V, Weinberg R, Greene M. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene Nature 1984, 312: 545-548. PMID: 6504162, DOI: 10.1038/312545a0.
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenSchechter A, Stern D, Vaidyanathan L, Decker S, Drebin J, Greene M, Weinberg R. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 1984, 312: 513-516. PMID: 6095109, DOI: 10.1038/312513a0.
- Organization of the IBV GenomeStern D, Sefton B. Organization of the IBV Genome 1984, 173: 11-23. PMID: 6331104, DOI: 10.1007/978-1-4615-9373-7_2.
- Coronavirus proteins: biogenesis of avian infectious bronchitis virus virion proteins.Stern DF, Sefton BM. Coronavirus proteins: biogenesis of avian infectious bronchitis virus virion proteins. Journal Of Virology 1982, 44: 794-803. PMID: 6294329, PMCID: PMC256336, DOI: 10.1128/jvi.44.3.794-803.1982.
- Coronavirus proteins: structure and function of the oligosaccharides of the avian infectious bronchitis virus glycoproteins.Stern DF, Sefton BM. Coronavirus proteins: structure and function of the oligosaccharides of the avian infectious bronchitis virus glycoproteins. Journal Of Virology 1982, 44: 804-12. PMID: 6294330, PMCID: PMC256337, DOI: 10.1128/jvi.44.3.804-812.1982.
- Synthesis of coronavirus mRNAs: kinetics of inactivation of infectious bronchitis virus RNA synthesis by UV light.Stern DF, Sefton BM. Synthesis of coronavirus mRNAs: kinetics of inactivation of infectious bronchitis virus RNA synthesis by UV light. Journal Of Virology 1982, 42: 755-9. PMID: 6283182, PMCID: PMC256903, DOI: 10.1128/jvi.42.2.755-759.1982.
- Structural analysis of virion proteins of the avian coronavirus infectious bronchitis virus.Stern DF, Burgess L, Sefton BM. Structural analysis of virion proteins of the avian coronavirus infectious bronchitis virus. Journal Of Virology 1982, 42: 208-19. PMID: 6283141, PMCID: PMC256062, DOI: 10.1128/jvi.42.1.208-219.1982.
- The avian coronavirus multiplication strategy.Stern D, Burgess L, Linesch S, Kennedy I. The avian coronavirus multiplication strategy. Advances In Experimental Medicine And Biology 1981, 142: 185-91. PMID: 6278881, DOI: 10.1007/978-1-4757-0456-3_16.
- Coronavirus multiplication strategy. II. Mapping the avian infectious bronchitis virus intracellular RNA species to the genome.Stern DF, Kennedy SI. Coronavirus multiplication strategy. II. Mapping the avian infectious bronchitis virus intracellular RNA species to the genome. Journal Of Virology 1980, 36: 440-9. PMID: 6253669, PMCID: PMC353660, DOI: 10.1128/jvi.36.2.440-449.1980.
- Complete list of published work in My Bibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/david.stern.1/bibliography/40866180/public/?sort=date&direction=ascending Complete list of published work in My Bibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/david.stern.1/bibliography/40866180/public/?sort=date&direction=ascending